Drug Profile


Alternative Names: DMP 266; L 741211; L 743725; L 743726; Stocrin; Sustiva

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Bristol-Myers Squibb
  • Class Alkynes; Antiretrovirals; Benzoxazines; Cyclopropanes; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Jul 2014 Bristol-Myers Squibb initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT02164812)
  • 03 May 2013 Registered for HIV-1 infections (in infants, in children) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top